Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
January 29, 2025 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
January 13, 2025 08:00 ET | Cabaletta Bio
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 26, 2024 08:00 ET | Cabaletta Bio
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024 07:00 ET | Cabaletta Bio
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – –...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024 07:00 ET | Cabaletta Bio
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024 08:00 ET | Cabaletta Bio
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024 16:30 ET | Cabaletta Bio
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024 08:00 ET | Cabaletta Bio
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:00 ET | Cabaletta Bio
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024 08:00 ET | Cabaletta Bio
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...